![]() |
Hematology/Oncology Research Studies: Open for Enrollment | Date: 02/15/19 |
---|
NCT#/Phase: | NCT01842672 Phase 1/2a |
---|---|
IRB#: | 2017-037 |
Description: | This study will evalute the maximum tolerated dose and response rate of the combination of mitoxantrone and clofarabine as reinduction therapy for patients with poor risk refractory/relapsed acute leukemia and high grade non-Hodgkin lymphoma (NHL). |
Inclusion: | Individuals who are <= 30 years of age with relapsed or refractory acute leukemia or NHL. |
Enrollment Status: | Open for enrollment |
Sponsor: | New York Medical College |
Principal Investigator(s): | Jennifer Michlitsch, MD |
Contact(s): | Anu Agrawal, MD (510-428-3885 x3539) Jennifer Michlitsch, MD |
Study Link: | https://clinicaltrials.gov/ct2/show/NCT01842672 |